128 related articles for article (PubMed ID: 19330168)
1. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Ross JS
Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
[TBL] [Abstract][Full Text] [Related]
2. Targeting the function of the HER2 oncogene in human cancer therapeutics.
Moasser MM
Oncogene; 2007 Oct; 26(46):6577-92. PubMed ID: 17486079
[TBL] [Abstract][Full Text] [Related]
3. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.
Taube SE; Clark GM; Dancey JE; McShane LM; Sigman CC; Gutman SI
J Natl Cancer Inst; 2009 Nov; 101(21):1453-63. PubMed ID: 19855077
[TBL] [Abstract][Full Text] [Related]
4. Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists.
Bornstein-Quevedo L; de Anda-González J; Lara-Torres CO; Flores-Gutiérrez JP; Dorantes-Heredia R; Bautista-Piña V; Zaragoza-Vargas P; Alcaraz-Wong A; Soto-Sañudo AK; Mendoza-Ramírez S; Salamanca-García M; Loyola-Rodríguez G; Gómez-Macías GS; Murguia-Perez M; De Luna-Sánchez M; Villalobos-Valencia R; Talamantes E; Arce-Salinas C
J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793049
[TBL] [Abstract][Full Text] [Related]
5. A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.
Gray MA; Tao RN; DePorter SM; Spiegel DA; McNaughton BR
Chembiochem; 2016 Jan; 17(2):155-8. PubMed ID: 26556305
[TBL] [Abstract][Full Text] [Related]
6. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Ross JS; Slodkowska EA; Symmans WF; Pusztai L; Ravdin PM; Hortobagyi GN
Oncologist; 2009 Apr; 14(4):320-68. PubMed ID: 19346299
[TBL] [Abstract][Full Text] [Related]
7. HER2 in breast cancer: a review and update.
Krishnamurti U; Silverman JF
Adv Anat Pathol; 2014 Mar; 21(2):100-7. PubMed ID: 24508693
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer biomarker measurements and standards.
Cole KD; He HJ; Wang L
Proteomics Clin Appl; 2013 Jan; 7(1-2):17-29. PubMed ID: 23341234
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.
Triulzi T; Bianchi GV; Tagliabue E
Future Oncol; 2016 Jun; 12(11):1413-28. PubMed ID: 27007660
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer: updated guideline recommendations for HER2 testing.
Rakha EA; Ellis IO
Nat Rev Clin Oncol; 2014 Jan; 11(1):8-9. PubMed ID: 24322598
[TBL] [Abstract][Full Text] [Related]
12. HER2 status is an important biomarker in guiding personalized HER2 therapy.
Carney WP
Per Med; 2005 Nov; 2(4):317-324. PubMed ID: 29788570
[TBL] [Abstract][Full Text] [Related]
13. The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPin G3 for HER2 imaging in oncology.
Ehsasatvatan M; Kohnehrouz BB; Gholizadeh A; Ofoghi H; Shanehbandi D
Biol Res; 2022 Oct; 55(1):32. PubMed ID: 36274167
[TBL] [Abstract][Full Text] [Related]
14. Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update.
Mohanty SS; Sahoo CR; Padhy RN
Genes Dis; 2022 May; 9(3):648-658. PubMed ID: 35782984
[TBL] [Abstract][Full Text] [Related]
15. Site-Specific Protein Modifications by an Engineered Asparaginyl Endopeptidase from
Chen Y; Zhang D; Zhang X; Wang Z; Liu CF; Tam JP
Front Chem; 2021; 9():768854. PubMed ID: 34746098
[TBL] [Abstract][Full Text] [Related]
16. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer.
Rocha-Filho DR; Peixoto RD; Weschenfelder RF; Rego JFM; Riechelmann R; Coutinho AK; Fernandes GS; Jacome AA; Andrade AC; Murad AM; Mello CAL; Miguel DSCG; Gomes DBD; Racy DJ; Moraes ED; Akaishi EH; Carvalho ES; Mello ES; Filho FM; Coimbra FJF; Capareli FC; Arruda FF; Vieira FMAC; Takeda FR; Cotti GCC; Pereira GLS; Paulo GA; Ribeiro HSC; Lourenco LG; Crosara M; Toneto MG; Oliveira MB; de Lourdes Oliveira M; Begnami MD; Forones NM; Yagi O; Ashton-Prolla P; Aguillar PB; Amaral PCG; Hoff PM; Araujo RLC; Di Paula Filho RP; Gansl RC; Gil RA; Pfiffer TEF; Souza T; Ribeiro U; Jesus VHF; Costa WL; Prolla G
Ecancermedicalscience; 2021; 15():1195. PubMed ID: 33889204
[TBL] [Abstract][Full Text] [Related]
17. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer.
Peixoto RD; Rocha-Filho DR; Weschenfelder RF; Rego JFM; Riechelmann R; Coutinho AK; Fernandes GS; Jacome AA; Andrade AC; Murad AM; Mello CAL; Miguel DSCG; Gomes DBD; Racy DJ; Moraes ED; Akaishi EH; Carvalho ES; Mello ES; Filho FM; Coimbra FJF; Capareli FC; Arruda FF; Vieira FMAC; Takeda FR; Cotti GCC; Pereira GLS; Paulo GA; Ribeiro HSC; Lourenco LG; Crosara M; Toneto MG; Oliveira MB; de Lourdes Oliveira M; Begnami MD; Forones NM; Yagi O; Ashton-Prolla P; Aguillar PB; Amaral PCG; Hoff PM; Araujo RLC; Filho RPDP; Gansl RC; Gil RA; Pfiffer TEF; Souza T; Jr UR; Jesus VHF; Jr WLC; Prolla G
Ecancermedicalscience; 2020; 14():1126. PubMed ID: 33209117
[TBL] [Abstract][Full Text] [Related]
18. Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
van Dooijeweert C; Deckers IAG; Baas IO; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2019 Jun; 175(2):487-497. PubMed ID: 30825048
[TBL] [Abstract][Full Text] [Related]
19. Can composite digital monitoring biomarkers come of age? A framework for utilization.
Kovalchick C; Sirkar R; Regele OB; Kourtis LC; Schiller M; Wolpert H; Alden RG; Jones GB; Wright JM
J Clin Transl Sci; 2017 Dec; 1(6):373-380. PubMed ID: 29707260
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
